Skip to main content
SpringerLink
Log in

Akuttherapie der Migräneattacke

  • Chapter
Migräne

Part of the book series: Optimierte Arzneimitteltherapie ((ARZNEIMITTELTH.))

  • 93 Accesses

Zusammenfassung

Migräneattacken werden typischerweise von vegetativen Begleiterscheinungen wie Übelkeit und Erbrechen begleitet. Dabei kommt es zu einer Verringerung der Peristaltik, so daβ oral eingenommene Medikamente nur verzögert ins Duodenum und in tiefere Dünndarmabschnitte transportiert werden, wo sie dann auch verzögert resorbiert werden. Die Wirksamkeit oral eingenommener Medikamente, seien es Analgetika oder spezifische Migränemittel, hängt aber überwiegend von der Zeit ab, bis die maximale Konzentration im Serum erreicht wird. Dies erklärt, warum häufig Analgetika —allein eingenommen — nicht ausreichend wirksam sind.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Andersson PG, Hinge HH, Johansen O, Andersen CU, Lademann A, Gotzsche PC (1989) Double-blind study of naproxen vs placebo in the treatment of acute migraine attacks. Cephalalgia 9:29–32

    Article  PubMed  CAS  Google Scholar 

  • Bannwarth B, Demotes-Mainard F, Schaeverbeke T, Labat L, Dehais J (1995) Central analgesic effects of aspirin-like drugs. Fund Clin Pharmacol 9:1–7

    Article  CAS  Google Scholar 

  • Bates D, Ashford E, Dawson R, Ensink F-BM, Gilhus NE, Olesen J, Pilgrim AJ, Shevlin P (1994) Subcutaneous sumatriptan during the migraine aura. Neurology 44:1587–1592

    PubMed  CAS  Google Scholar 

  • Becker WJ, on behalf of the Study Group (1995) A placebo-controlled, dose-defining study of sumatriptan nasal spray in the acute treatment of migraine. Cephalagia 15 (Suppl 14): 239

    Google Scholar 

  • Brown EG, Endersby CA, Smith RN, Talbot JCC (1991) The safety and tolerability of sumatriptan: an overview. Eur Neurol 31:339–344

    Article  PubMed  CAS  Google Scholar 

  • Brune K, Beck WS, Geisslinger G, Menzel-Soglowek S, Peskar BM, Peskar BA (1991) Aspirin-like drugs may block pain independently of prostaglandin synthesis inhibition. Experientia 47:257–261

    Article  PubMed  CAS  Google Scholar 

  • Buzzi G, Moskowitz MA (1990) The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br J Pharmacol 99:202–206

    PubMed  CAS  Google Scholar 

  • Buzzi G, Sakas DE, Moskowitz MA (1989) Indomethacin and acetylsalicylic acid block neurogenic plasma protein extravasation in rat dura mater. Eur J Pharmacol 165:251–258

    Article  PubMed  CAS  Google Scholar 

  • Buzzi MG, Carter WB, Shimizu THH, Moskowitz MA (1991) Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion. Neuropharmacology 30:1193–1200

    Article  PubMed  CAS  Google Scholar 

  • Buzzi MG, Moskowitz MA (1991) Evidence for 5-HT1B/1D receptors mediating the antimigraine effect of sumatriptan and dihydroergotamine. Cephalalgia 11:165–168

    Article  PubMed  CAS  Google Scholar 

  • Cady RK, Wendt JK, Kirchner JR, Sargent JD, Rothrock JF, Skaggs H (1991) Treatment of acute migraine with subcutaneous sumatriptan. JAMA 265:2831–2835

    Article  PubMed  CAS  Google Scholar 

  • Chabriat H, Danchot J, Grippon P, Bousser MG (1994) Combined oral lysine acetylsalicylate and metoclopramide in the acute treatment of migraine: a multicentre double-blind placebo-controlled study. Cephalalgia 14:297–300

    Article  PubMed  CAS  Google Scholar 

  • Connor HE, Fenjuk W, Beattie DT (1998) Naratriptan: biological profile in animal models relevant to migraine. Cephalalgia im Druck

    Google Scholar 

  • Cumberbatch MJ, Hill RG, Hargreaves RJ (1997) Rizatriptan has central antinociceptive effects against durally evoked responses. Eur J Pharmacol 328:37–40

    Article  PubMed  CAS  Google Scholar 

  • Dahlöf C (1993) Placebo-controlled clinical trials with ergotamine in the acute treatment of migraine. Cephalalgia 13:166–171

    Article  PubMed  Google Scholar 

  • Dichgans J, Diener HC, Gerber WD, Verspohl EJ, Kukiolka H, Kluck M (1984) Analgetika-induzierter Dauerkopfschmerz. Dtsch med Wschr 109:369–373

    Article  PubMed  CAS  Google Scholar 

  • Diener HC, Klein KB (1996) The first comparison of the efficacy and safety of 311C90 and sumatriptan in the treatment of migraine. Poster, 3rd European Headache Conference, Sardinia

    Google Scholar 

  • Dixon R, Gillotin C, Gibbens M, Posner J, Peck RW (1997a) The pharmacokinetics and effects on blood pressure of multiple doses of the novel anti-migraine drug zolmitriptan (311C90) in healthy volunteers. Br J Clin Pharmacol 3:273–281

    Google Scholar 

  • Dixon R, Warrander A (1997) The clinical pharmacokinetics of zolmitriptan. Cephalalgia 17:15–20

    Article  PubMed  Google Scholar 

  • Dixon RM, Meire HB, Evans DH, Watt H, On N, Posner J, Rolan PE (1997b) Peripheral vascular effects and pharmacokinetics of the antimigraine compound, zolmitriptan, in combination with oral ergotamine in healthy volunteers. Cephalalgia 17:639–646

    Article  PubMed  CAS  Google Scholar 

  • Dowson AJ, on behalf of the Study Group (1996) An open, dose-titration study evaluating 25 mg, 50 mg and 100 mg doses of oral sumatriptan in the acute treatment of migraine. Poster, 2nd EFNS Congress, Rome

    Google Scholar 

  • Earl NL (1997) Zolmitriptan (311C90), a new acute treatment for migraine: an overview of safety. In: Oleson J, Tfelt-Hansen P (Hrsg.) Frontiers of Headache Research. Headache Treatment: Trial Methodology and New Drugs. Lippin-cott-Raven, New York, 267–272

    Google Scholar 

  • Edmeads JG, Millson DS (1997) Tolerability profile of zolmitriptan (Zomig; 311C90), a novel dual central and peripherally acting 5-HT1B/1D agonist. Cephalalgia 17:41–52

    PubMed  Google Scholar 

  • Feniuk W, Humphrey PPA, Perren M (1989) The selective carotid arterial vasoconstrictor action of GR43175 in anaesthetized dogs. Brit J Pharmacol 96:83–90

    CAS  Google Scholar 

  • Ferrari MD (1996) The clinical effectiveness of 311C90 in the acute treatment of migraine. Eur Neurol 36 (Suppl 2):4–7

    Article  PubMed  CAS  Google Scholar 

  • Ferrari MD (1997) 311C90: Increasing the options for the therapy with effective acute antimigraine 5-HT1B/D receptor agonists. Neurology 48 (Suppl 3):21–24

    Google Scholar 

  • Gijsman H, Kramer MS, Sargent J, Tuchman M, Matzura-Wolfe D, Polis A, Teall J, Block G, Ferrari MD (1997) Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine. Cephalalgia 17:647–651

    Article  PubMed  CAS  Google Scholar 

  • Goadsby PJ, Edvinsson L (1994) Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311C90. Headache 34: 394–399

    Article  PubMed  CAS  Google Scholar 

  • Goadsby PJ, Edvinsson L, Ekman R (1990) Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 28:183–187

    Article  PubMed  CAS  Google Scholar 

  • Goadsby PJ, Gundlach AL (1991) Localization of 3H-Dihydroergotamine-binding sites in the cat central nervous system: relevance to migraine. Ann Neurol 29:91–94

    Article  PubMed  CAS  Google Scholar 

  • Goadsby PJ, Hoskin KJ (1996) Inhibition of trigeminal neurons by intravenous administration of the serotonin (5-HT)lB/D receptor agonist zolmitriptan (311C90): Are brain stem sites therapeutic target in migraine? Pain 67:355–359

    Article  PubMed  CAS  Google Scholar 

  • Goadsby PJ, Knight Y (1997) Inhibition of trigeminal neurones after intravenous administration of naratriptan trough an action at 5-hydroxytryptamine (5-HT1B/1D) receptors. Br J Pharmacol 122:918–922

    Article  PubMed  CAS  Google Scholar 

  • Göbel H, Boswell D, Winter PDO, Crisp A (1997) A comparison of the efficacy and tolerability of naratriptan and sumatriptan among migraineurs with a history of frequent (50% of attacks) headache recurrence. Poster, VIIIth IHS Congress, Amsterdam.

    Google Scholar 

  • Göbel H, Ernst M, Jeschke J, Keil R, Weigle L (1992) Acetylsalicylic acid activates antinociceptive brain-stem reflex activity in headache patients and in healthy subjects. Pain 48:187–195

    Article  PubMed  Google Scholar 

  • Gross MLP, Kay J, Turner AM, Jewsbury J, Cleal AL (1995) Long-term efficacy of subcutaneous sumatriptan using a novel self-injector. Headache 35:601–606

    Article  PubMed  CAS  Google Scholar 

  • Hämäläinen ML, Hoppu K, Santavuori P (1997) Sumatriptan for migraine attacks in children: A randomized placebo-controlled study. Do children with migraine attacks respond to oral sumatriptan differently from adults? Neurology 48:1100–1103

    PubMed  Google Scholar 

  • Havanka-Kanniainen H (1989) Treatment of acute migraine attack: ibuprofen and placebo compared. Headache 29:507–509

    Article  PubMed  CAS  Google Scholar 

  • Humphrey PPA, Feniuk W, Motevalian M, Parsons A A, Whalley ET (1991) The vasoconstrictor action of sumatriptan on human isolated dura mater. In: Fozard JR, Saxena PR (Hrsg.) Serotonin: molecular biology, receptors and functional effects. Birkhäuser, Basel, 420–429

    Google Scholar 

  • Johnson ES, Ratcliffe DM, Wilkinson M (1985) Naproxen sodium in the treatment of migraine. Cephalalgia 5:5–10

    Article  PubMed  CAS  Google Scholar 

  • Kaube H, Hoskin KL, Goadsby PJ (1993) Intravenous acetylsalicylic acid inhibits central trigeminal neurons in the dorsal horn of the upper cervical spinal cord in the cat. Headache 33:541–544

    Article  PubMed  CAS  Google Scholar 

  • Kaube H, Hoskin KL, Goadsby PJ (1993) Sumatriptan inhibits central trigeminal neurons only after blood-brain barrier disruption. Cephalalgia 13 (Suppl 13):41

    Google Scholar 

  • Kaube H, May A, Diener HC, Pfaffenrath V (1994) Sumatriptan. BMJ 308:1573

    Google Scholar 

  • Kirch W, Ziegler A (1989) Pharmakologische Grundlagen der Anwendung von Dihydroergotamin. Neurologie Psychiatrie 2:43–48

    Google Scholar 

  • Klassen A, Elkind A AM, Webster C, Laurenza A, on behalf of the Naratriptan S2WA3001 Study Group (1997) Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. Headache 37:630–645

    Article  Google Scholar 

  • Klassen AC, Gabriel H, Hobbs S, Woessner M (1995) Safety and efficacy of sumatriptan suppositories in the acute treatment of migraine attacks. Poster, VII. IHS Congress, Toronto

    Google Scholar 

  • Kunka RL, Hussey EK, Shaw S, Warner P, Aubert B, Richard I, Fowler PA, Pakes GE (1997) Safety, tolerability, and pharmacokinetics of sumatriptan suppositories following single and multiple doses in healthy volunteers. Cephalalgia 17:532–540

    Article  PubMed  CAS  Google Scholar 

  • Lipton RB, Stewart WF (1997) Clinical applications of zolmitriptan (Zomig, 311C90). Cephalalgia 17 (Suppl 18):53–59

    PubMed  Google Scholar 

  • Longmore J, Hargreaves RJ, Boulanger CM, Brown MJ, Desta B, Ferro A, Schofield WN, Taylor AA, Hill RG (1997) Comparison of the vasoconstrictor properties of the 5-HT1D-receptor agonists rizatriptan (MK-462) and sumatriptan in human isolated coronary artery: outcome of two independent studies using different experimental protocols. Funct Neurol 12:3–9

    PubMed  CAS  Google Scholar 

  • MacGregor EA, Wilkinson M, Bancroft K (1993) Domperidone plus paracetamol in the treatment of migraine. Cephalalgia 13:124–127

    Article  PubMed  CAS  Google Scholar 

  • Maclntyre PD, Bhargava B, hogg KJ, Gemmili JD, Hillis WS (1993) Effect of subcutaneous sumatriptan, a selective 5-HT1 agonist, on the systemic, pulmonary and coronary circulation. Circulation 87:401–405

    Google Scholar 

  • Martin G, Dixon R, Seaber E (1997) Preclinical and clinical pharmacology of Zolmitriptan (311C90): A novel antimigraine agent. In: Oleson J, Tfelt-Han-sen P (Hrsg.) Headache Treatment: Trial Methodology and New Drugs. Lippincott-Raven, New York, 257–262

    Google Scholar 

  • Martin GR (1996) Inhibition of the trigemino-vascular system with 5-HT1D agonist drugs: Selectively targeting additional sites of action. Eur.Neurol 36 (Suppl 2):13–18

    Article  PubMed  CAS  Google Scholar 

  • Martin GR, Robertson AD, MacLennan SJ, Prentice DJ, Barret VJ, Buckingham J, Honey AC, Giles H, Moncada S (1997) Receptor specificity and trigeminovascular inhibitory actions of a novel 5-HT(lB/lD) receptor partial agonist, 311C90 (zolmitriptan). Br J Pharmacol 2:157–164

    Article  Google Scholar 

  • Massiou H, on behalf of the Study Group (1996) A comparison of sumatriptan nasal spray 20 mg and intranasal dihydroergotamin in the acute treatment of migraine. Poster, 3rd European Headache Conference, Sardinia

    Google Scholar 

  • Mathew NT, Asgharnejad M, Peykamian M, Laurenza A, on behalf of the Naratriptan S2WA3003 Study Group (1997) Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. Neurology 49:1485–1490

    PubMed  CAS  Google Scholar 

  • Monstadt I, on behalf of the Study Group (1995) The long-term tolerability, safety and efficacy of 25 mg sumatriptan suppositories in the acute treatment of migraine. Poster, VII. IHS Congress, Toronto

    Google Scholar 

  • Nebe J, Heier M, Diener HC (1995) Low-dose ibuprofen in self-medication of mild to moderate headache: a comparison with acetylsalicylic acid and placebo. Cephalalgia 15:531–535

    Article  PubMed  CAS  Google Scholar 

  • O’Callaghan J, for the Study Group (1993) Long-term efficacy of subcutaneous sumatriptan using a novel self-injector. Cephalalgia 13 (Suppl 13): 161

    Google Scholar 

  • Parsons AA, Whalley ET, Feniuk W, Connor HE, Hunmphrey PPA (1989) 5-HT1-like receptors mediate 5-hydroxytryptamine-induced contraction of human isolated basilar artery. Brit J Pharmacol 96:434–449

    CAS  Google Scholar 

  • Patten JP (1991) Clinical experience with oral sumatriptan: a placebo-controlled, dose-ranging study. J Neurol 238 (Suppl 1):S62–S65

    Article  PubMed  Google Scholar 

  • Pearce I, Frank GJ, Pearce JMS (1983) Ibuprofen compared with paracetamol in migraine. Practitioner 227:465–467

    PubMed  CAS  Google Scholar 

  • Pfaffenrath V on behalf of the Study Group (1996) A study comparing the efficacy, safety, and tolerability of oral sumatriptan 25 mg, 50 mg and 100 mg doses in the acute treatment of migraine. Poster, 2nd EFNS Congress, Rome

    Google Scholar 

  • Pilgrim AJ, Blakeborough P (1994) The clinical efficacy of sumatriptan in the acute treatment of migraine. Rev Contemp Pharmacother 5: 95–309

    Google Scholar 

  • Rapoport AM, Ramadan NM, Adelmann JU, Mathew NT, Elkind AH, Kudrow DB, Earl NL, on behalf of the 017 Clinical Trial Study Group (1997) Optimizing the dose of zolmitriptan (Zomig 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose-finding study. Neurology 49:1210–1218

    PubMed  CAS  Google Scholar 

  • Rolan P (1997) Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig, 311C90). Cephalalgia 17:21–27

    PubMed  Google Scholar 

  • Rosenkranz S, Deutsch HJ, Erdmann E (1997) “Saint Anthony’s Fire”: Ergotamin-induzierte Gefäβspasmen als Ursache akuter ischämischer Syndrome. Dtsch Med Wochenschr 14:450–454

    Article  Google Scholar 

  • Ross-Lee LM, Eadie MJ, Heazlewood V, Bochner F, Tyrer JH (1983) Aspirin pharmacokinetics in migraine. The effect of metoclopramide. Eur J Clin Pharmacol 24:777–785

    Article  PubMed  CAS  Google Scholar 

  • Ryan R, Elkind A, Baker CC, Mullican W, DeBussy S, Asgharnejad M (1997) Sumatriptan nasal spray for the acute treatment of migraine. Neurology 49:1225–1230

    PubMed  CAS  Google Scholar 

  • Saito K, Markowitz S, Moskowitz MA (1988) Ergot alkaloids block neurogenic extravasation in dura mater: proposed action in vascular headaches. Ann Neurol 24:732–737

    Article  PubMed  CAS  Google Scholar 

  • Salonen R on behalf of the Study Group (1996) Patient preference among 25 mg, 50 mg and 100 mg oral doses of sumatriptan. Poster, 2nd EFNS Congress, Rome

    Google Scholar 

  • Salonen R, Ashford E, Dahlöf C, Dawson R, Gilhus NE, Lüben V, Noronha D, Warter J, for the International Study Group (1994) Intranasal sumatriptan for the acute treatment of migraine. J Neurol 241:463–469

    Article  PubMed  CAS  Google Scholar 

  • Schoenen J, Sawyer J (1997) Zolmitriptan (Zomig, 311C90), a novel dual central and peripheral 5HT1B/1D agonist: an overview of efficacy. Cephalalgia 17 Suppl 18:28–40

    PubMed  Google Scholar 

  • Sciberras DG, Polvino WJ, Gertz BJ, Cheng H, Stepanavage M, Wittreich J, Olah T, Edwards M, Mant T (1997) Initial human experience with MK-462 (rizatriptan): a novel 5-HT1D agonist. Br J Clin Pharmacol 43:49–54

    Article  PubMed  CAS  Google Scholar 

  • Seaber E, On N, Dixon RM, Gibbens M, Leavens WJ, Liptrot J, Chittick G, Posner J, Rolant PE, Peck RW (1997) The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90). Br J Clin Pharmacol 43:579–587

    Article  PubMed  CAS  Google Scholar 

  • Shepheard SL, Williamson DJ, Beer MS, Hill RG, Hargreaves RJ (1997) Differential effects of 5-HT1B/D receptor agonists on neurogenic dural plasma extravasation and vasodilation in anaesthetized rats. Neuropharmacology 36:525–533

    Article  Google Scholar 

  • Solomon GD, Cade RK, Klapper JA, Earl NL, Saper JR, Ramadan NM, on behalf of the 042 Clinical Trial Study Group (1997) Clinical efficacy and tolerability of 2,5 mg zolmitriptan for the acute treatment of migraine. Neurology 49:1219–1225

    PubMed  CAS  Google Scholar 

  • Tansey MJB, Pilgrim AJ, Lloyd K (1993) Sumatriptan in acute treatment of migraine. J Neurol Sci 114:109–116

    Article  PubMed  CAS  Google Scholar 

  • Tfelt-Hansen P, Henry P, Mulder LJ, Schaeldewaert RG, Schoenen J, Chazot G (1995) The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet 346:923–926

    Article  PubMed  CAS  Google Scholar 

  • Tfelt-Hansen P, Olesen J (1984) Effervescent metoclopramide and aspirin (Migravess) versus effervescent aspirin or placebo for migraine attacks: a double-blind study. Cephalalgia 4:107–111

    Article  PubMed  CAS  Google Scholar 

  • The Multinational Oral Sumatriptan and Cafergot Comparative Study Group (1991) A randomized, double-blind comparison of sumatriptan and Cafergot in the acute treatment of migraine. Eur Neurol 31:314–322

    Article  Google Scholar 

  • The Oral Sumatriptan and Aspirin plus Metoclopramide Comparative Study Group (1992) A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. Eur Neurol 32:177–184

    Article  Google Scholar 

  • The Oral Sumatriptan Dose-Defining Study Group (1991) Sumatriptan — an oral dose- defining study. Eur Neurol 31:300–305

    Article  Google Scholar 

  • The Oral Sumatriptan International Multiple-Dose Study Group (1991) Evaluation of a multiple-dose regimen of oral sumatriptan for the acute treatment of migraine. Eur Neurol 31:306–313

    Article  Google Scholar 

  • The Subcutaneous Sumatriptan International Study Group (1991) Treatment of migraine attacks with sumatriptan. N Engl J Med 325:316–321

    Article  Google Scholar 

  • The Sumatriptan Auto-Injector Study Group (1991) Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device. Eur Neurol 31:323–331

    Article  Google Scholar 

  • Touchon J, Bertin L, Pilgrim AJ, Ashford E, Bès A (1996) A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute treatment of migraine. Neurology 47:361–365

    PubMed  CAS  Google Scholar 

  • Visser (1997) Pharmacologic profile and clinical efficacy of rizatriptan. Vortrag VIII. IHS Congress, Amsterdam

    Google Scholar 

  • Visser WH, for the Study Group (1993) Does a combined regimen of subcutaneous followed by oral sumatriptan prevent headache recurrence. Cephalalgia 13, Suppl. 13:189

    Google Scholar 

  • Visser WH, Jaspers NMWH, de Vriend RHM, Ferrari MD (1996) Risk factors for headache recurrence after sumatriptan: a study in 366 migraine patients. Cephalalgia 16:264–269

    Article  PubMed  CAS  Google Scholar 

  • Visser WH, Terwindt GM, Reines SA, Jiang K, Lines CR, Ferrari MD, for the Dutch/US Rizatriptan Study Group (1997) Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Arch Neurol 53:1132–1137

    Google Scholar 

  • Volans GN (1975) The effect of metoclopramide on the absorption of effervescent aspirin in migraine. Br J Clin Pharmacol 2:57–63

    PubMed  CAS  Google Scholar 

  • Weiller C, May A, Limmroth V, Jüptner M, Kaube H, van Schayck R, Coenen HH, Diener HC (1995) Brain stem activation in spontaneous human migraine attacks. Nature Medicine 1:658–660

    Article  PubMed  CAS  Google Scholar 

  • Wilkinson M, Pfaffenrath V, Schoenen J, Diener HC, Steiner T (1995) Migraine and cluster headache — their management with sumatriptan: a critical rewiew of the current clinical experience. Cephalalgia 15:337–357

    Article  PubMed  CAS  Google Scholar 

  • Williamsen DJ, Shepheard SL, Hill RG, Hargreaves RJ (1997) The novel anti-migraine agent rizatriptan inhibtis neurogenic durai vasodilation and extravasation. Eur J Pharmacol 328:61–64

    Article  Google Scholar 

  • Zagami AS, for the 311C90 Long-Term Study Group (1997) 311C90: long-term efficacy and tolerability profile for the acute treatment of migraine. Neurology 48 (Suppl 3):S25–S28

    Google Scholar 

  • Zschiedrich M, Heidrich H, Dienes HP (1985) Ergotismus: Epidemiologie, Pathogenese, Histomorphologie, Diagnostik und Therapie. Med Klinik 80:721–727

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Neurologie, Universität Essen, Hufelandstraße 55, 45122, Essen, Deutschland

    Professor Dr. Hans-Christoph Diener

Authors
  1. Professor Dr. Hans-Christoph Diener
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Diener, HC. (1999). Akuttherapie der Migräneattacke. In: Migräne. Optimierte Arzneimitteltherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59858-6_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-59858-6_5

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-63950-3

  • Online ISBN: 978-3-642-59858-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation